The spillover effect of the CIIE drives Sanofi's China business to accelerate and deepen its localization layout
楚一帆
发表于 2024-11-7 20:49:01
133
0
0
As the largest healthcare company in France, Sanofi has participated in the China International Import Expo for the seventh consecutive year. Benefiting from the spillover effect of the CIIE, Sanofi showcased its global R&D pipeline, which includes 12 potential heavyweight products, as well as 7 innovative achievements in the field of immunology at this year's CIIE. In addition, Sanofi announced further promotion of localization, reached a strategic cooperation with Shangyao Holdings, and signed a series of contracts.
Sanofi CEO Paul Hudson said that the CIIE provides an important platform for Sanofi, which not only promotes further opening up of the Chinese market, but also creates more opportunities for potential cooperation between various fields around the world. Sanofi aims to transform the medical model and deeply understands the scale and speed of innovation in China. We look forward to supporting the development of China's world-class medical ecosystem and benefiting patients worldwide.
Sanofi's star product in the field of immune inflammation, Dabitou& reg; He is one of the witnesses and witnesses of 'China's speed'. In September of this year, Dabitou& reg; The new indication for chronic obstructive pulmonary disease has been approved in China, and it is reported that this approval was granted before the approval of the US FDA. Compared to the European Union and the United States, China has the shortest approval time, once again breaking the record for innovative drugs benefiting Chinese patients. Its other product, Saiyining& reg; In 2021, we will participate in the CIIE and embark on our journey in China. In just one year, we will achieve a "three-level leap" from approval, listing to inclusion in medical insurance at the "Chinese speed" in 2023.
Sanofi Greater China President Shi Wang stated that in the past seven years, thanks to the strong "spillover effect" of the CIIE, Sanofi's business development in China has indeed accelerated. We have also witnessed the Chinese government's firm commitment to promoting pharmaceutical innovation and health through the CIIE. This year, we will once again attend the meeting with multiple innovative achievements in the field of immunology that are "first" or "only" in China and globally, and further deepen cooperation and dialogue with local partners. The Chinese market is crucial to Sanofi, and we always focus on the unmet medical needs of patients, continuously strengthen investment in scientific innovation, business model innovation, and actively build a Chinese pharmaceutical and health innovation ecosystem, and help promote the high-quality development of the industry
During the CIIE, Sanofi announced a strategic partnership with Shangyao Holdings. Based on the good cooperation foundation in the past, both parties will expand their cooperation in the pharmaceutical business field, optimize cooperation models, improve operational efficiency, focus on key products, enhance market accessibility, and promote higher-level industrial chain innovation and cross integration. This is one of the largest, most extensive, and deepest strategic partnerships between the pharmaceutical industry and industry, marking a new step for Sanofi and Shangyao Holdings in promoting collaborative innovation and development in the pharmaceutical industry.
During the CIIE, Sanofi held multiple important signing ceremonies and events at its booth, continuously exploring and practicing localization, increasing investment and layout in the Chinese market. It also signed a memorandum of cooperation with Kaihui Fund to help develop China's pharmaceutical innovation ecosystem, achieve technological breakthroughs and commercial success, and unleash the global potential of Chinese innovation; Signed a strategic cooperation agreement with Tianjing Biotechnology regarding the development, production, and commercialization of the CD73 antibody uliledlimab in Greater China.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Tesla China's latest statement: not true! Trump suddenly spreads big news! Has Musk become a big winner again?
- Johnson&Johnson China reported layoffs! Layoff employees: Surgical department has the highest number of layoffs
- The Nasdaq China Golden Dragon Index closed up 1.71%, with most popular Chinese concept stocks rising
- The Nasdaq China Golden Dragon Index closed up 1.71%, with most popular Chinese concept stocks rising
- Yum China repurchases 50000 shares and pays approximately $2.4 million
- FSD authorizes SAIC to layout Robotaxi? Tesla China: Never Connected
- Starbucks responds to rumors of 'considering selling shares in China business': committed to developing in China and striving to find the best growth path
- JD's instant retail adds to its efforts: 'Instant Delivery' launches first batch of over 100 brands
- Starbucks responds to rumors of considering selling equity in its China business: committed to long-term development in the Chinese market and striving to find the best growth path
- The Nasdaq China Golden Dragon Index closed down 1%, with most popular Chinese concept stocks falling
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 昨天 16:36
- 支持
- 反对
- 回复
- 收藏
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 前天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 前天 14:29
- 支持
- 反对
- 回复
- 收藏